Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Johnson & Johnson (JNJ): Among Best Stocks To Invest In From Conservative Stock Portfolio
Best Stocks To Invest In. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against ...
Johnson & Johnson (JNJ): Among the Best Psychedelic Stocks to Buy in 2025
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other psychedelic ...
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...